Transdermal delivery of dehydroepiandrosterone
US5709878A · kind A · utility
16Cited by
15References
16Claims
0Family size
Inventors
Key dates
| Filing date | Aug 2, 1996 |
| Grant date | Jan 20, 1998 |
| Priority date | — |
| Expiry date | Aug 2, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a novel transdermal delivery system for dehydroepiandrosterone (DHEA). Using phospholipids as vehicles, DHEA can be administered into and through the skin when topically applied. Numerous advantages apply to this modality of therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.